SOFDRA (Sofpironium Bromide) Patent Expiration, LOE Window & CMS Spending

SOFDRA (Sofpironium Bromide) by Botanix Sb: FDA Orange Book core substance LOE 2040-05-22, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $968 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBotanix Sb
FDA Application & PathwayN217347 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-22
Last Listed Patent or Exclusivity Date2040-05-22
Orange Book Patents (*PED Extensions)21 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($968 intro WAC)